|4-[[(3s)-3-二甲基氨基吡咯烷-1-基]甲基]-N-[4-甲基-3-[(4-嘧啶-5-基嘧啶-2-基)氨基]苯基]-3-(三氟甲基)苯甲酰胺|CsnPharm

CAS No.: 887650-05-7

Lyn-IN-1/巴非替尼 Catalog No. CSN12740

Synonyms: Bafetinib analog

Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor with potential antineoplastic activity, it is an orally bioavailable 2-phenylaminopyrimidine derivative.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Bcr-Abl fusion tyrosine kinase is formed because of a reciprocal chromosomal translocation between chromosomes 9 and 22, producing the Philadelphia chromosome. Bcr-Abl is expressed in chronic myeloid leukemia(CML) and a chronic of acute lymphocytic leukemia^[2]. Lyn-IN-1, synonyms for Bafetinib(INNO-406), is a tyrosine kinase inhibitor that against wild-type Bcr-Abl in human erythroleukemia K562 cells and human embryonic kidney 293T cells with IC50 values of 11nM and 22nM, respectively. Lyn-IN-1 also suppresses the phosphorylation of platelet-derived growth factor receptor (PDGFR) and c-Kit. In vitro, Lyn-IN-1 effectively inhibited the kinase activity of both Tyr393-phosphorylated and Tyr393-unphosphorylated forms of Abl with respective IC50 values of 72nM and 30nM, suggesting that Lyn-IN-1 had sufficiently high affinity for Bcr-Abl to enable it to bind even to an unfavourable conformation of the kinase. Lyn-IN-1 also inhibited the phosphorylation of Bcr-Abl bearing M244V, G250E, Q252H, Y253F, E255K, E255V, F317L, M351T, E355G, E359V, H396P and F486S mutations with IC50 values ranging in 81-1400nM, but it did not inhibit the phosphorylation of the T315I mutation. Lyn-IN-1 inhibited proliferation of K562 and U937 cells with IC50 values of 11nM and 10μM, respectively^[3]. Lyn-IN-1 inhibited proliferation of Human mast cell (HMC)-1 with IC50 value of 51nM. Lyn-IN-1 inhibited KIT phosphorylation and inducted apoptosis in HMC-1 cells^[4]. In vivo, oral administration of Lyn-IN-1 at 0.2mg/kg twice daily for 10 days significantly inhibited tumor growth, while at 20mg/kg/day completely inhibited tumor growth without adverse effects in Balb/c-nu/nu mouse bearing xenografted KU812 cells. Oral administration of Lyn-IN-1 at 200mg/kg/day significantly prolonged the survival of the Balb/c-nu/nu mice intravenously injected with BaF3/wt cells. In addition, treatment of mice bearing BaF3 cells expressing Bcr-Abl bearing M244V, G250E, Q252H, Y253F, E255K, M351T or H396P mutations with Lyn-IN-1 at a dose of 20mg/kg/day showed significant prolongation of survival without any apparent signs of toxicity^[3].
作用机制The characteristic structural features of Lyn-IN-1 are a trifl uoromethyl group on the D ring that occupies a hydrophobic pocket of the Abl ligand-binding site and an adjacent dimethylaminopyrrolidine E ring whose rotation is restricted by the trifl uoromethyl group^[3].
参考文献

[1] WO2014169128A1
[2] Skorski T. BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons. Chemistry & Biology, 2011, 18(11): 1352-1353
[3] Niwa T, Asaki T, Kimura S, et al. NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor. Analytical chemistry insights, 2007, 2(1): 93-106
[4] Pan J , Alfonso Quintás-Cardama, Manshouri T , et al. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer science, 2007, 98(8):1223-1225

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.7343 mL
- 8.6713 mL
- 17.3426 mL
- 5 mM
- 0.3469 mL
- 1.7343 mL
- 3.4685 mL
- 10 mM
- 0.1734 mL
- 0.8671 mL
- 1.7343 mL

技术信息

CAS号	887650-05-7	储存条件	粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C30H31F3N8O	运输	蓝冰
分子量	576.62	别名	Bafetinib analog

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Lyn-IN-1/巴非替尼 Catalog No. CSN12740

靶点选择性

请登录您的专属账户

确认信息